- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Cadila Pharmaceuticals Launches Avastin Biosimilar in India
Cadila Pharmaceuticals has launched a bevacizumab biosimilar referencing Avastin in India. Bevacizumab is used for the treatment of colorectal, breast, and lung cancers, among others.
Ahmedabad-based Cadila Pharmaceuticals said it has launched a bevacizumab biosimilar (Bevaro) on the Indian market for the treatment of multiple cancers.
The biosimilar referencing Genentech’s Avastin is used in patients with ovarian cancer, glioblastoma multiforme, colorectal cancer, breast cancer, lung cancer, cervical cancer, and kidney cancer.
Bevaro will be made available in a single-dose vials of 100 mg and 400 mg.
Cadila “has always been focused in making sure high quality, affordable and life-saving treatments are within the reach of patients. Biosimilar products like Bevaro are safe and more efficacious compared to conventional treatment medicines,” the company said in a statement.
Cadila said it plans to launch multiple other biosimilar products in 2020 for the Indian market.
More About Cadila Pharmaceuticals
Cadila is one of the largest privately held pharmaceutical companies in India and was founded in 1951. It has more than 850 formulation products and manufactures 38 active pharmaceutical ingredients. Its therapeutic specialties include cardiovascular, gastrointestinal, analgesic, anti-infective and antibiotic, respiratory, antidiabetic, immunology, and oncology products.
The company has seen setbacks from the coronavirus disease 2019 (COVID-19) this year. In May, its Dholka formulations plant in Ahmedabad was shut down after more than 2 dozen employees tested positive for COVID-19, according to Reuters.
The plant was subjected to deep sanitization to bring it back up to health standards, according to a financial press report.
Companies in India have been eager to get a share of the global biosimilars market. Biocon has been a standout example of an Indian company that has succeeded in broadening its scope to an international standing.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
